ATE247980T1 - Verwendung von an glycoprotein gpiib/iiia bindenden substanzen zur vermeidung von stenosis und restenosis - Google Patents

Verwendung von an glycoprotein gpiib/iiia bindenden substanzen zur vermeidung von stenosis und restenosis

Info

Publication number
ATE247980T1
ATE247980T1 AT95902460T AT95902460T ATE247980T1 AT E247980 T1 ATE247980 T1 AT E247980T1 AT 95902460 T AT95902460 T AT 95902460T AT 95902460 T AT95902460 T AT 95902460T AT E247980 T1 ATE247980 T1 AT E247980T1
Authority
AT
Austria
Prior art keywords
restenosis
immunoglobulins
iiia
prevent
specific
Prior art date
Application number
AT95902460T
Other languages
English (en)
Inventor
Barry S Coller
Harlan F Weisman
Original Assignee
Centocor Inc
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22523494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE247980(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centocor Inc, Univ New York State Res Found filed Critical Centocor Inc
Application granted granted Critical
Publication of ATE247980T1 publication Critical patent/ATE247980T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Prostheses (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT95902460T 1993-11-05 1994-11-07 Verwendung von an glycoprotein gpiib/iiia bindenden substanzen zur vermeidung von stenosis und restenosis ATE247980T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14792893A 1993-11-05 1993-11-05
PCT/US1994/012779 WO1995012412A1 (en) 1993-11-05 1994-11-07 Platelet-specific chimeric immunoglobulin and methods of use therefor

Publications (1)

Publication Number Publication Date
ATE247980T1 true ATE247980T1 (de) 2003-09-15

Family

ID=22523494

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95902460T ATE247980T1 (de) 1993-11-05 1994-11-07 Verwendung von an glycoprotein gpiib/iiia bindenden substanzen zur vermeidung von stenosis und restenosis

Country Status (15)

Country Link
EP (2) EP0725655B2 (de)
JP (1) JPH09504795A (de)
CN (2) CN1140295C (de)
AT (1) ATE247980T1 (de)
AU (2) AU1172495A (de)
CA (1) CA2175214A1 (de)
DE (1) DE69433091T3 (de)
DK (1) DK0725655T4 (de)
ES (1) ES2204937T5 (de)
HK (1) HK1054682B (de)
NZ (2) NZ502819A (de)
PT (1) PT725655E (de)
RU (1) RU2158135C2 (de)
UA (1) UA37249C2 (de)
WO (1) WO1995012412A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770198A (en) * 1988-05-18 1998-06-23 The Research Foundation Of The State Of New York Platelet-specific chimeric 7E3 immunoglobulin
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
NZ513882A (en) * 1995-06-07 2001-09-28 Centocor Inc Platelet-specific chimeric immunogloulin and method of use thereof
JP2001512480A (ja) * 1997-02-19 2001-08-21 セントコア，インコーポレイテッド 持続的薬物送達およびそれに有用な組成物
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
RU2200481C2 (ru) * 2001-02-22 2003-03-20 Научно-Исследовательский Институт Трансплантологии И Искусственных Органов Способ лечения острой сердечной недостаточности
FR2843396B1 (fr) * 2002-08-07 2005-04-15 Bio Rad Pasteur Anticorps specifiques pour le diagnostic de l'insuffisance cardiaque
RU2240136C1 (ru) * 2003-04-10 2004-11-20 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н.Габричевского МЗ РФ" Композиция, содержащая иммуноглобулины и целевые добавки

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1297815C (en) * 1985-06-07 1992-03-24 Barry S. Coller Fibrinogen blocking monoclonal antibody
CA1297816C (en) * 1985-06-14 1992-03-24 Barry S. Coller Platelet function inhibiting monoclonal antibody fragment
KR940009084B1 (ko) * 1988-05-18 1994-09-29 체크 포인트 시스템스, 인코오퍼레이티드 자기 및 공명회로 검출용 안테나 시스템
ATE124267T1 (de) * 1989-04-03 1995-07-15 Centocor Inc Blutplättchenspezifische immunokonjugate.
DK0606391T3 (da) * 1991-09-30 1999-05-03 Biogen Inc Inhibering af karforsnævring under anvendelse af anti-PADGEM-antistoffer
WO1993013133A1 (en) * 1991-12-20 1993-07-08 Yamanouchi Pharmaceutical Co., Ltd. HUMAN TYPE ANTIBODY REACTIVE WITH GPIIb/IIIa

Also Published As

Publication number Publication date
NZ527820A (en) 2005-04-29
EP0725655B1 (de) 2003-08-27
HK1054682A1 (en) 2003-12-12
CA2175214A1 (en) 1995-05-11
WO1995012412A1 (en) 1995-05-11
CN1142189A (zh) 1997-02-05
HK1054682B (zh) 2006-05-04
AU1172495A (en) 1995-05-23
PT725655E (pt) 2004-01-30
DE69433091T2 (de) 2004-06-03
DE69433091T3 (de) 2009-07-30
ES2204937T3 (es) 2004-05-01
RU2158135C2 (ru) 2000-10-27
CN1230201C (zh) 2005-12-07
DE69433091D1 (de) 2003-10-02
ES2204937T5 (es) 2009-07-06
EP0725655A1 (de) 1996-08-14
UA37249C2 (uk) 2001-05-15
AU8959398A (en) 1999-01-14
JPH09504795A (ja) 1997-05-13
DK0725655T4 (da) 2009-05-18
EP1334730A3 (de) 2003-12-03
EP0725655B2 (de) 2009-04-15
DK0725655T3 (da) 2004-01-05
NZ502819A (en) 2002-09-27
CN1140295C (zh) 2004-03-03
EP1334730A2 (de) 2003-08-13
CN1404877A (zh) 2003-03-26

Similar Documents

Publication Publication Date Title
DE10299038I2 (de) Pl{ttchen-spezifisches Chim{risches immunglobulin.
DE3888186D1 (de) Modulärer zusammenbau von antikörpergenen, dadurch hergestellte antikörper und deren anwendung.
ATE268818T1 (de) Ctla4-mutantmoleküle und deren verwendung
DE58909458D1 (de) Antigenkonstrukte von "Major Histocompatibility Complex" Klasse I Antigenen mit spezifischen Trägermolekülen, ihre Herstellung und Verwendung.
AU706584C (en) Immunoglobulin variants
ATE168013T1 (de) Humanisierte chimäre anti-''icam-1'' antikörper, herstellungsverfahren und verwendung
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
AU1042192A (en) Recombinant antibodies specific for a growth factor receptor
EP0325262A3 (en) Cloned genes encoding ig-cd4 fusion proteins and the use thereof
DE69429723D1 (de) Stressproteine und ihre verwendung
EE04752B1 (et) Monoklonaalne antikeha, seda tootev hübridoom ja antikeha kasutamine
ATE429450T1 (de) Chimärische dr4 antikörper und ihre verwendung
ATE247980T1 (de) Verwendung von an glycoprotein gpiib/iiia bindenden substanzen zur vermeidung von stenosis und restenosis
DK0665853T3 (da) Multimere polyvalente antitrombotiske midler
DE69624259D1 (de) Vaskulare endothelzelle-wachstumsfaktor antiidotypische antikörper und ihre verwendung als arzneimittel
ES2179824T3 (es) Anticuerpos humanizados reactivos contra el antigeno gpiib/iiia.
WO1996040250A3 (en) Platelet-specific chimeric immunoglobulin and methods of use therefor
UA88604C2 (ru) Применение антитела, которое связывается с альфа-4-интегрином, для лечения демиелинизирующего заболевания

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0725655

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 0725655

Country of ref document: EP